AGP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.26 PKR | +6.59% |
|
+18.57% | +34.06% |
| Apr. 30 | AGP Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | AGP Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.43B 69.85M | Sales 2025 * | - | Capitalization | 26.65B 95.81M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.37 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 1,574 |
| Yield 2024 * |
3.94% | Yield 2025 * |
-
| Free-Float | 16.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.59% | ||
| 1 week | +18.57% | ||
| Current month | +18.57% | ||
| 1 month | +18.75% | ||
| 3 months | +44.24% | ||
| 6 months | +54.50% | ||
| Current year | +34.06% |
1 week
80.00
95.06
1 month
75.6695.06
Current year
60.2195.06
1 year
46.0095.06
3 years
46.00158.99
5 years
46.00158.99
10 years
46.00158.99
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | Dec. 31 | |
Junaid Aslam
DFI | Director of Finance/CFO | - | - |
Shumaila Amir
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 18-06-06 | |
| Chief Executive Officer | - | Dec. 31 | |
Kamran Nishat
BRD | Director/Board Member | - | 15-11-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 95.18 | +0.98% | 1,011,265 |
| 24-05-09 | 94.26 | +6.59% | 1,588,521 |
| 24-05-08 | 88.43 | -0.55% | 963,863 |
| 24-05-07 | 88.92 | +7.50% | 984,362 |
| 24-05-06 | 82.72 | +1.53% | 303,718 |
End-of-day quote Pakistan S.E., May 08, 2024
More quotes
AGP Limited is a Pakistan-based pharmaceutical company. The principal activities of the Company include import, marketing, export, dealership, distribution, wholesale, and manufacturing of all kinds of pharmaceutical products. The principal activities of the Company include import, marketing, export, dealership, distribution, wholesale, and manufacturing of various kinds of pharmaceutical products. It owns a range of products catering to distinct therapeutic needs of the market. It consists of Holding Company's pharmaceutical segment and related products, and OBS AGP's pharmaceutical segment. It offers a diverse portfolio of products in internal medicine, gynecology, pediatrics, nutraceutical, neuropsychiatry, cardiometabolic, hepatology, and orthopedic. Its products include Afdol, Nebcin, Exotan, Nergab, Febuxin, Zerifax, Protege, Maxna, and Rigix, among others. Its subsidiary includes OBS AGP (Private) Limited (OBS AGP). OBS AGP is in the business of trading pharmaceutical products.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
95.18
PKR
Average target price
100
PKR
Spread / Average Target
+5.06%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.06% | 95.82M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- AGP Stock